Zahra Mahmoudjafari, Pharm.D., MBA

Health care leaders warn that payer variability, not clinical readiness, is the biggest obstacle to scaling cell and gene therapy, and that current reimbursement models may not hold.

Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, payer alignment, and workflows protecting safety and finances.

Zahra Mahmoudjafari shares how The University of Kansas Cancer Center builds sustainable cell and gene therapy programs amid new CMS access rules.

Early pharmacy leadership helps health systems build safe, sustainable cell and gene therapy programs, aligning contracts, workflows, regulations and payer realities.

Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.